Author:
Le Dortz Lisa Lucie,Rouxel Clotilde,Leroy Quentin,Ducongé Frédéric,Boulouis Henri-Jean,Haddad Nadia,Deshuillers Pierre Lucien,Lagrée Anne-Claire
Abstract
AbstractA. phagocytophilum is a zoonotic and tick-borne bacterium, threatening human and animal health. Many questions persist concerning the variability of strains and the mechanisms governing the interactions with its different hosts. These gaps can be explained by the difficulty to cultivate and study A. phagocytophilum because of its strict intracellular location and the lack of specific tools, in particular monoclonal antibodies, currently unavailable. The objective of our study was to develop DNA aptamers against A. phagocytophilum, or molecules expressed during the infection, as new study and/or capture tools. Selecting aptamers was a major challenge due to the strict intracellular location of the bacterium. To meet this challenge, we set up a customized selection protocol against an enriched suspension of A. phagocytophilum NY18 strain, cultivated in HL-60 cells. The implementation of SELEX allowed the selection of three aptamers, characterized by a high affinity for HL-60 cells infected with A. phagocytophilum NY18 strain. Interestingly, the targets of these three aptamers are most likely proteins expressed at different times of infection. The selected aptamers could contribute to increase our understanding of the interactions between A. phagocytophilum and its hosts, as well as permit the development of new diagnostic, therapeutic or drug delivery appliances.
Funder
AgroParisTech
Laboratoire d’Excellence “Integrative Biology of Emerging Infectious Diseases”
Publisher
Springer Science and Business Media LLC
Reference60 articles.
1. Dugat, T., Lagrée, A.-C., Maillard, R., Boulouis, H.-J. & Haddad, N. Opening the black box of Anaplasma phagocytophilum diversity: Current situation and future perspectives. Front. Cell. Infect. Microbiol. 5, 1 (2015).
2. Matei, I. A. et al. A review on the eco-epidemiology and clinical management of human granulocytic anaplasmosis and its agent in Europe. Parasit. Vectors 12, 599 (2019).
3. CDC. Anaplasmosis home | CDC. Centers for Disease Control and Prevention https://www.cdc.gov/anaplasmosis/index.html (2022). Accessed on September, 2023.
4. Dumler, J. S. The biological basis of severe outcomes in Anaplasma phagocytophilum infection. FEMS Immunol. Med. Microbiol. 64, 13–20 (2012).
5. Eleftheriou, A., Cole, D., Kieffer, J. & Pesapane, R. Molecular prevalence of Anaplasma marginale and associated risk factors in beef cattle herds from Ohio: a cross-sectional study. J. Am. Vet. Med. Assoc. 260, 1839–1843 (2022).